Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease.
Reid F, Singh D, Albayaty M, Moate R, Jimenez E, Sadiq MW, Howe D, Gavala M, Killick H, Williams A, Krishnan S, Godwood A, Shukla A, Hewitt L, Lei A, Kell C, Pandya H, Newcombe P, White N, Scott IC, Cohen ES. Reid F, et al. Among authors: scott ic. Clin Pharmacol Ther. 2024 Mar;115(3):565-575. doi: 10.1002/cpt.3147. Epub 2024 Jan 24. Clin Pharmacol Ther. 2024. PMID: 38115209 Clinical Trial.
Interleukin-33 Signaling Controls the Development of Iron-Recycling Macrophages.
Lu Y, Basatemur G, Scott IC, Chiarugi D, Clement M, Harrison J, Jugdaohsingh R, Yu X, Newland SA, Jolin HE, Li X, Chen X, Szymanska M, Haraldsen G, Palmer G, Fallon PG, Cohen ES, McKenzie ANJ, Mallat Z. Lu Y, et al. Among authors: scott ic. Immunity. 2020 May 19;52(5):782-793.e5. doi: 10.1016/j.immuni.2020.03.006. Epub 2020 Apr 8. Immunity. 2020. PMID: 32272082 Free PMC article.
Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction.
England E, Rees DG, Scott IC, Carmen S, Chan DTY, Chaillan Huntington CE, Houslay KF, Erngren T, Penney M, Majithiya JB, Rapley L, Sims DA, Hollins C, Hinchy EC, Strain MD, Kemp BP, Corkill DJ, May RD, Vousden KA, Butler RJ, Mustelin T, Vaughan TJ, Lowe DC, Colley C, Cohen ES. England E, et al. Among authors: scott ic. Sci Rep. 2023 Jun 17;13(1):9825. doi: 10.1038/s41598-023-36642-y. Sci Rep. 2023. PMID: 37330528 Free PMC article.
Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex.
Strickson S, Houslay KF, Negri VA, Ohne Y, Ottosson T, Dodd RB, Huntington CC, Baker T, Li J, Stephenson KE, O'Connor AJ, Sagawe JS, Killick H, Moore T, Rees DG, Koch S, Sanden C, Wang Y, Gubbins E, Ghaedi M, Kolbeck R, Saumyaa S, Erjefält JS, Sims GP, Humbles AA, Scott IC, Romero Ros X, Cohen ES. Strickson S, et al. Among authors: scott ic. Eur Respir J. 2023 Sep 28;62(3):2202210. doi: 10.1183/13993003.02210-2022. Print 2023 Sep. Eur Respir J. 2023. PMID: 37442582 Free PMC article.
Nasal IL-13 production identifies patients with late-phase allergic responses.
Campion NJ, Villazala-Merino S, Thwaites RS, Stanek V, Killick H, Pertsinidou E, Zghaebi M, Toth J, Fröschl R, Perkmann T, Gangl K, Schneider S, Ristl R, Scott IC, Cohen ES, Molin M, Focke-Tejkl M, Regelsberger G, Hansel TT, Valenta R, Niederberger-Leppin V, Eckl-Dorna J. Campion NJ, et al. Among authors: scott ic. J Allergy Clin Immunol. 2023 Nov;152(5):1167-1178.e12. doi: 10.1016/j.jaci.2023.06.026. Epub 2023 Aug 1. J Allergy Clin Immunol. 2023. PMID: 37536510 Free article. Clinical Trial.
151 results